Skip to main content
Premium Trial:

Request an Annual Quote

MDS Proteomics Signs Five-Year Deal with Cephalon

NEW YORK, Jan. 7-MDS Proteomics and Cephalon have struck a five-year joint drug development agreement, the two companies said today.

 

Under the agreement, MDS Proteomics will supply various proteomics technologies, including chemiproteomics, phosphorylation fingerprinting and protein interaction mapping, in order to improve clinical development of Cephalon's candidate compounds for central nervous system disease.

 

In return, MDS Proteomics will receive milestone payments and royalties on product sales. Cephalon has also purchased a $30 million 5 percent convertible note from MDS Proteomics. The note, which is due in 2010, is convertible into MDS Proteomics common stock at $22 per share.

 

MDS Proteomics is a privately held systems biology company based in Toronto.

 

Cephalon, a publicly held drug development firm, is headquartered in West Chester, Pa.

 

 

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.